BR112018073951A2 - forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida - Google Patents

forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida

Info

Publication number
BR112018073951A2
BR112018073951A2 BR112018073951A BR112018073951A BR112018073951A2 BR 112018073951 A2 BR112018073951 A2 BR 112018073951A2 BR 112018073951 A BR112018073951 A BR 112018073951A BR 112018073951 A BR112018073951 A BR 112018073951A BR 112018073951 A2 BR112018073951 A2 BR 112018073951A2
Authority
BR
Brazil
Prior art keywords
indazol
ylamino
piperazin
benzamide
pyran
Prior art date
Application number
BR112018073951A
Other languages
English (en)
Inventor
Tomasi Attilio
OTTAIANO Giovanni
Candiani Ilaria
Original Assignee
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl
Publication of BR112018073951A2 publication Critical patent/BR112018073951A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

a presente invenção se refere a uma forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida, processo para sua preparação, sua utilidade no tratamento de doenças causadas por atividade de proteína quinase desregulada e composições farmacêuticas que contêm a mesma.
BR112018073951A 2016-05-24 2017-05-18 forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida BR112018073951A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662340797P 2016-05-24 2016-05-24
PCT/EP2017/061919 WO2017202674A1 (en) 2016-05-24 2017-05-18 New crystalline form of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide

Publications (1)

Publication Number Publication Date
BR112018073951A2 true BR112018073951A2 (pt) 2019-02-26

Family

ID=58709993

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018073951A BR112018073951A2 (pt) 2016-05-24 2017-05-18 forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida

Country Status (14)

Country Link
US (2) US10738037B2 (pt)
EP (2) EP3464276B1 (pt)
JP (2) JP7094228B2 (pt)
KR (1) KR102441736B1 (pt)
CN (1) CN109153669B (pt)
AU (1) AU2017271458B2 (pt)
BR (1) BR112018073951A2 (pt)
CA (1) CA3024208C (pt)
ES (1) ES2899953T3 (pt)
HK (1) HK1259405A1 (pt)
IL (1) IL263004B (pt)
MX (1) MX2018014298A (pt)
PL (1) PL3464276T3 (pt)
WO (1) WO2017202674A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2899953T3 (es) * 2016-05-24 2022-03-15 Nerviano Medical Sciences Srl Nueva forma cristalina de n-[5-(3,5-difluoro-bencil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetrahidro-piran-4-ilamino)-benzamida
AU2020319662B2 (en) 2019-07-31 2024-02-29 F. Hoffmann-La Roche Ag New pharmaceutical formulation
US20220372024A1 (en) * 2019-11-01 2022-11-24 Johnson Matthey Public Limited Company Crystalline forms of entrectinib
CN113024521B (zh) * 2019-12-09 2023-01-17 武汉九州钰民医药科技有限公司 一种制备恩曲替尼的方法
CN111171009B (zh) * 2020-01-10 2022-07-12 安礼特(上海)医药科技有限公司 恩曲替尼晶型及其制备方法
CN113801062B (zh) * 2020-06-15 2023-05-26 沈阳药科大学 3-氨基-5-(3,5-二氟苄基)-1h-吲唑的制备方法
CN112336723B (zh) * 2020-12-11 2023-09-26 江南大学 制备用于降低trpv4与nox2耦联度的药物的方法
EP4273144A1 (en) * 2021-02-03 2023-11-08 Qilu Pharmaceutical Co., Ltd. Crystal form of entrectinib and preparation method therefor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5506674B2 (ja) * 2007-07-20 2014-05-28 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤として活性な置換インダゾール誘導体
RU2602071C2 (ru) * 2012-05-23 2016-11-10 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Способ получения n-[5-(3,5-дифторбензил)-1н-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидропиран-4-иламино)бензамида
TWI672141B (zh) * 2014-02-20 2019-09-21 美商醫科泰生技 投予ros1突變癌細胞之分子
ES2899953T3 (es) 2016-05-24 2022-03-15 Nerviano Medical Sciences Srl Nueva forma cristalina de n-[5-(3,5-difluoro-bencil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetrahidro-piran-4-ilamino)-benzamida

Also Published As

Publication number Publication date
US11091469B2 (en) 2021-08-17
EP3464276B1 (en) 2021-09-01
MX2018014298A (es) 2019-03-14
JP2021042213A (ja) 2021-03-18
AU2017271458A1 (en) 2019-01-17
ES2899953T3 (es) 2022-03-15
US10738037B2 (en) 2020-08-11
WO2017202674A1 (en) 2017-11-30
US20190169173A1 (en) 2019-06-06
US20200325122A1 (en) 2020-10-15
KR102441736B1 (ko) 2022-09-13
PL3464276T3 (pl) 2022-04-04
JP2019516749A (ja) 2019-06-20
JP7154271B2 (ja) 2022-10-17
HK1259405A1 (zh) 2019-11-29
CA3024208C (en) 2022-07-26
AU2017271458B2 (en) 2020-11-26
CA3024208A1 (en) 2017-11-30
IL263004B (en) 2022-04-01
IL263004A (en) 2018-12-31
KR20190005236A (ko) 2019-01-15
JP7094228B2 (ja) 2022-07-01
CN109153669B (zh) 2021-12-24
EP3967689A1 (en) 2022-03-16
CN109153669A (zh) 2019-01-04
EP3464276A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
BR112018073951A2 (pt) forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
BR112014028841A2 (pt) processo para preparação de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-l-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
TN2019000281A1 (en) Ferroportin-inhibitor salts
CR20160310A (es) Composiciones farmacpeuticas que comprenden azd9291
CL2018001031A1 (es) Inhibidores de ferroportina novedosos
CR20200617A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
NZ734516A (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n’-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
NI201500142A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
NI201500031A (es) Métodos para tratar la enfermedad de alzheimer y composiciones farmacéuticas de los mismos.
BR112016028749A2 (pt) composto, forma cristalina, composição farmacêutica, e, método para o tratamento de uma doença.
BR112017004173A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica.
BR112015019412A2 (pt) inibidores de bace1
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
EA201890532A1 (ru) Новые аннелированные бензамиды
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
BR112017024633A2 (pt) novo amidoeteroaril aroil hidrazida etino
CL2017002229A1 (es) Inhibidores de bace1.
BR112018013364A2 (pt) forma cristalina e composição farmacêutica
EA201792558A1 (ru) Противогрибковый 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-триазол-1-ил)метил)-5-(2,4-дифторфенил)тетрагидрофуран-3-ил)метокси)-3-метилфенил)пиперазин-1-ил)-n-(2-гидроксициклогексил)бензамид или его фармацевтически приемлемая соль
BR112018073396A2 (pt) combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
EA202190452A1 (ru) Ингибиторы cdk8/19
BR112016007031A8 (pt) composição farmacêutica oral sólida, processo para preparar a composição farmacêutica oral sólida, e uso de uma composição farcêutica oral sólida
BR112019006401A2 (pt) glicinato de metformina, composições farmacêuticas que compreendem o mesmo e métodos de uso do mesmo
BR112017012558A2 (pt) Composições de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h- indazol-5-il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il) fenil)-3,6-diidropiridin-1(2h)-il)-2-oxoetil)-3-(metiltio) pirrolidina-3-carboxamida para preparações farmacêuticas

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]